title: Incidence of human cytomegalovirus infection in patients with refractory solid tumors receiving nonmyeloablative allogeneic stem cell transplants versus recipients of standard SCT for hematologic malignancies.
abstract: Human cytomegalovirus (HCMV) infection is the most frequent infectious complication after conventional allogeneic stem cell transplantation (alloSCT). From December 1998 to December 2002, we prospectively monitored HCMV reactivation in 59 patients affected by solid tumors and undergoing nonmyeloablative alloSCT (NST). Patients were allografted from HLA-identical sibling donors after fludarabine/cyclophosphamide-based conditioning regimens. Seventeen (28.8%) of 59 patients presented with HCMV antigenemia, and 14 received ganciclovir, with successful HCMV clearance in all cases. No patient developed HCMV viremia or disease. The median time to HCMV reactivation was 54 days (range, 16-245 days) after NST. These patients were compared with a cohort of hematologic patients who were treated with conventional myeloablative alloSCT. Matching criteria included HCMV risk group, stem cell source, donor type, and age. In the myeloablative group, HCMV active infection was observed in 47 (85.4%) of 55 patients at a median time of 30 days (range, 13-64 days) after alloSCT, and HCMV infection occurred more frequently ( P < .001) and earlier ( P = .001) than in NST patients. Patients affected with solid tumors undergoing NST had a reduced and delayed incidence of HCMV active infection.
authors.affiliation: U. O. Oncologia Medica I, IRCCS, Fondazione Salvatore Maugeri, Pavia, Italy. azambelli@fsm.it
authors.forename: A
authors.initials: A
authors.lastname: Zambelli
authors.forename: D
authors.initials: D
authors.lastname: Lilleri
authors.forename: P
authors.initials: P
authors.lastname: Pedrazzoli
authors.forename: J
authors.initials: J
authors.lastname: Peccatori
authors.forename: F
authors.initials: F
authors.lastname: Baldanti
authors.forename: V
authors.initials: V
authors.lastname: Fregoni
authors.forename: F
authors.initials: F
authors.lastname: Ciceri
authors.forename: D
authors.initials: D
authors.lastname: Caldera
authors.forename: M
authors.initials: M
authors.lastname: Renga
authors.forename: A A
authors.initials: AA
authors.lastname: Colombo
authors.forename: E P
authors.initials: EP
authors.lastname: Alessandrino
authors.forename: G
authors.initials: G
authors.lastname: Gerna
authors.forename: G A
authors.initials: GA
authors.lastname: Da Prada
authors.forename: S
authors.initials: S
authors.lastname: Siena
authors.forename: M
authors.initials: M
authors.lastname: Bregni
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D011446:Prospective Studies; D012307:Risk Factors; D014019:Tissue Donors